导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.33% | 2423/4773 |
| 近一周 | 0.24% | 1079/5467 |
| 近一月 | -6.96% | 3326/5421 |
| 近一季 | 12.69% | 171/5238 |
| 近半年 | 0.95% | 1419/4931 |
| 近一年 | -12.75% | 3517/4400 |
| 近两年 | 23.47% | 2561/2954 |
| 近三年 | -5.84% | 1998/2253 |
| 成立以来 | 4.97% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.98% 2601/4961 |
-4.23% 3495/5312 |
- - |
- - |
| 2025 | 7.31% 2930/4813 |
2.36% 1398/3635 |
2.78% 1362/4076 |
15.29% 2822/4524 |
-11.52% 4205/4813 |
| 2024 | -12.24% 2368/3463 |
-11.05% 2406/2808 |
-8.18% 2176/3014 |
16.80% 1347/3129 |
-8.00% 2821/3463 |
| 2023 | -11.18% 1376/2656 |
0.38% 1734/2280 |
-7.68% 1888/2385 |
-2.16% 629/2515 |
-2.04% 412/2655 |
| 2022 | -21.72% 1046/2207 |
-13.69% 818/1919 |
-0.26% 1609/2016 |
-16.22% 1427/2113 |
8.55% 259/2208 |
| 2021 | -6.08% 996/1822 |
-2.81% 708/1255 |
15.25% 233/1330 |
-12.40% 1306/1466 |
-4.28% 1476/1822 |
| 2020 | 66.29% 90/1250 |
8.33% 32/1028 |
30.34% 58/1067 |
8.88% 694/1164 |
8.17% 685/1184 |
| 2019 | 40.46% 252/1092 |
28.74% 296/754 |
-6.72% 519/804 |
9.96% 50/850 |
6.36% 619/918 |
| 2018 | -25.47% 353/834 |
- - |
- - |
- - |
-19.24% 663/691 |
| 2017 | 13.03% 265/714 |
- - |
- - |
- - |
- - |
| 2016 | -13.78% 329/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 申万菱信中证申万医药生物指数(LOF)A VS. 长安沪深300非周期A(740101) |